2022 Revenues ($USD) : $58,054,000,000.00
2022 R&D spend : $6,510,000,000.00
2022 Number of Employees : 50,000
Fiscal Year End : 12/31/22
Leader : CEO Richard Gonzalez

After Abbott Laboratories spun out AbbVie in 2013, the North Chicago, Illinois–based firm has cemented its reputation as a pharma heavyweight. AbbVie reported strong quarterly performance and a highly productive year in 2022, with full-year adjusted earnings per share of $13.77, marking double-digit growth. Total net revenues exceeded $58 billion, up 5.1% operationally, driven by Skyrizi and Rinvoq, which generated nearly $7.7 billion in combined sales. AbbVie has evolved into a leading biopharmaceutical company with a well-diversified portfolio, including rapid development and the launch of Skyrizi and Rinvoq across major indications. Company officials anticipate that by 2027, these two products will collectively surpass Humira's peak revenues, with significant growth expected through the end of the decade. AbbVie also focuses on novel heme and solid tumor assets for oncology, neuroscience, and aesthetics, and has a strong financial position for long-term growth. —BB